SYBX
Closed
Synlogic Inc
1.18
-0.09 (-7.09%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.27
Day's Range: 1.18 - 1.27
Send
sign up or login to leave a comment!
When Written:
0.6223
Synlogic Inc is a biotechnology company that is focused on developing synthetic biotics, which are living medicines designed to treat a range of diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Synlogic's synthetic biotics are engineered to perform specific functions in the body, such as breaking down toxic substances or producing therapeutic molecules. The company is currently developing synthetic biotics for a variety of conditions, including metabolic disorders, cancer, and rare genetic diseases.
The company's lead product candidate is SYNB1618, which is being developed for the treatment of phenylketonuria (PKU), a rare genetic disorder that causes a buildup of phenylalanine in the blood. Synlogic is also developing synthetic biotics for the treatment of cancer, including a synthetic biotic that is designed to activate the immune system to attack cancer cells.
Synlogic has partnerships with a number of pharmaceutical companies, including AbbVie, Ginkgo Bioworks, and Roche. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol SYBX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Synlogic's synthetic biotics are engineered to perform specific functions in the body, such as breaking down toxic substances or producing therapeutic molecules. The company is currently developing synthetic biotics for a variety of conditions, including metabolic disorders, cancer, and rare genetic diseases.
The company's lead product candidate is SYNB1618, which is being developed for the treatment of phenylketonuria (PKU), a rare genetic disorder that causes a buildup of phenylalanine in the blood. Synlogic is also developing synthetic biotics for the treatment of cancer, including a synthetic biotic that is designed to activate the immune system to attack cancer cells.
Synlogic has partnerships with a number of pharmaceutical companies, including AbbVie, Ginkgo Bioworks, and Roche. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol SYBX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!